MedTrace Logo

RSV Immunisation Status in Queensland (Australia)

NCT07615192 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-05-29

No results posted yet for this study

Summary

The primary objective of this study is to determine the nirsevimab immunisation rate in eligible infants (according to Queensland Paediatric Respiratory Syncytial Virus Prevention Program recommendation) in Queensland, Australia.

The study will focus on:

1\. Assessing the immunisation rates among eligible infants (born from 1 February 2024 to 15 April 2025) in their first Respiratory Syncytial Virus (RSV)-season in Queensland.

Secondary objectives of this study are as follows:

1. To analyse reasons of parents to decide for or against immunisation of their infant with nirsevimab.

1. This objective aims to assess potential influencing factors and evaluate the changes in acceptance across the three cohorts prior and post recommendation.
2. In this regard, demographic factors (e.g. education, income) will be included in the analysis where applicable to gain insights on their potential impact.
2. To assess immunisation rates for further subgroups, e.g. by: a) risk group (defined chronic condition or pre-term birth status), b) regional areas of Queensland.
3. To compare the vaccination coverage rate estimates with data captured via the Australian Immunisation Register.

Conditions

  • RSV Immunization

Interventions

BIOLOGICAL

Nirsevimab Respiratory Syncytial Virus monoclonal antibody

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practice

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-26
Primary Completion
2026-07-20
Completion
2026-07-20

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07615192 on ClinicalTrials.gov